Clinical ROI Opportunity Daxor’s Blood Volume Analyzer offers real time, precise blood volume data via a rapid, hand held system. This enables clinicians to tailor fluid management for high cost conditions such as heart failure and ICU patients, potentially reducing complications, lengths of stay, and readmissions in value based care settings. Focus conversations with cardiology, critical care, and hospital administrators on clinical outcomes and ROI, supported by FDA cleared status and ISO 13485 certification.

Regional Expansion Potential Expansion momentum from the Southwest Ohio BVA program launch demonstrates scalable deployment, enabling replication at additional premier cardiology facilities. Sales opportunities exist to partner with regional health systems and academic centers, leveraging the success story, clinician champions, and ongoing conferences for local pilots and wider rollouts.

Clinical Validation Edge New clinical data validating BVA accuracy against capillary leak indexes strengthens differentiation for critical care and cardiovascular departments. Use this evidence to approach intensivists, pulmonologists, nephrologists, and procurement teams, and to support reimbursement discussions and program adoption in hospital networks.

Portable Bedside Advantage Next generation portable BVA showcased for ACC 26 signals a bedside friendly solution that can be deployed across ED, ICU, OR, and step down units, reducing setup barriers and enabling rapid adoption in busy hospital environments. Target high throughput centers and contract service providers with demonstrations, pilot programs, and alliance opportunities with distributors.

Quality and Compliance ISO 13485 certification, FDA cleared status, and in house U.S. manufacturing provide procurement confidence and supply reliability for large scale deployments. Highlight the quality and regulatory readiness to hospital procurement and GPOs, emphasizing consistent product availability and compliance across multiple sites.